COMMUNIQUÉS West-GlobeNewswire

ProQR Announces Results for the Third Quarter of 2017

20/11/2017 - 13:00

Key updates Runway into the second half of 2019: cash of €39.7 million at end of Q3, increased by gross proceeds of approximately $20 million from an issuance of ordinary shares in November 2017 that will fund [...]

Emergent BioSolutions Receives FDA Approval to Manufacture ACAM2000 at Canton, Massachusetts Facility

20/11/2017 - 13:00

GAITHERSBURG, Md., Nov. 20, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS ) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application ( [...]

Kamada and Chiesi Farmaceutici S.p.A. Mutually Agree to Terminate European Distribution Agreement for Inhaled Alpha-1 Antitrypsin Therapy for Treatment of Alpha-1 Antitrypsin Deficiency

20/11/2017 - 13:00

Following Kamada’s Recent Withdrawal of European Marketing Authorization Application, Distribution Agreement Not Currently Warranted REHOVOT, Israel, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA ) (TASE: [...]

Intra-Cellular Therapies Receives FDA Fast Track Designation for Lumateperone for the Treatment of Schizophrenia

20/11/2017 - 13:00

NEW YORK, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ: ITCI ), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today [...]

Amphastar Pharmaceuticals to Present at the 29th Annual Piper Jaffray Healthcare Conference

20/11/2017 - 12:00

RANCHO CUCAMONGA, Calif., Nov. 20, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH ) announced today that Jason Shandell, President and Bill Peters, CFO will be presenting at the 29th Annual Piper [...]

Orphazyme A/S: Completion of the Offering and registration of share capital increase

20/11/2017 - 11:46

Company announcement No. 12/2017 Orphazyme A/S Ole Maaløes Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 20 November 2017 NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART [...]

TiGenix to present positive 52-week Phase III Cx601 data at EHA-SWG Scientific Meeting

20/11/2017 - 09:32

PRESS RELEASE TiGenix to present positive 52-week Phase III Cx601 data at EHA-SWG Scientific Meeting Leuven (BELGIUM) - November 20, 2017, 07:00h CET - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced [...]

TiGenix présentera les données favorables de la semaine 52 de l'essai de phase III de Cx601 à l'occasion de l'EHA-SWG Scientific Meeting

20/11/2017 - 09:32

COMMUNIQUÉ DE PRESSE TiGenix présentera les données favorables de la semaine 52 de l'essai de phase III de Cx601 à l'occasion de l'EHA-SWG Scientific Meeting Louvain (BELGIQUE) - 20 novembre 2017, 07h. CET - TiGenix NV [...]

Veritas’ Research Arm Cannevert Therapeutics Signs Letter of Intent with Fundación de Investigación (FDI) of Puerto Rico USA to Begin Human Trials of Its Lead Cannabis Strain for Pain

20/11/2017 - 09:05

VANCOUVER, British Columbia, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt: 2VP ), (“Veritas” or the “Company”) announces that its research arm, Cannevert Therapeutics Ltd. ("CTL [...]

Orphazyme A/S: No termination or withdrawal of Orphazyme's IPO

20/11/2017 - 08:39

Company announcement No. 11/2017 Orphazyme A/S Ole Maaløes Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 20 November 2017 NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART [...]

Prima BioMed Changes Its Name to Immutep Ltd

20/11/2017 - 07:59

SYDNEY, Australia, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima” or the “Company”) has announced a rebranding of the Company from Prima BioMed Ltd to Immutep Ltd (“Immutep”) [...]

Novartis drug Tasigna® (nilotinib) secures EU approval for first and second-line treatment of Ph+ CML-CP in children

20/11/2017 - 07:16

Tasigna is the first and only second-generation tyrosine kinase inhibitor approved in the EU for the treatment of Ph+ CML-CP in children Approval builds on a series of Tasigna regulatory milestones, including addition [...]

MDxhealth teams up with Pharmaceutical Company Ferrer for distribution of its Prostate Cancer test SelectMDx in Spain

20/11/2017 - 07:01

Promising market with an estimate of over 300.000 Spanish men with elevated PSA levels MDxHealth's urine test a non-invasive, molecular test clearly showing who could safely forego a painful biopsy, saving patients from [...]

MDxhealth fait équipe avec la société pharmaceutique Ferrer pour distribuer SelectMDx en Espagne

20/11/2017 - 07:01

Marché prometteur avec un nombre estimé de 300.000 hommes espagnols avec un taux de PSA élevé Le test urinaire moléculaire non-invasif de MDxHealth démontre clairement qui peut renoncer à une biopsie douloureuse en [...]

ALBATROSS with GLPG2222 shows positive clinical results in CF patients

19/11/2017 - 22:02

Evaluation of C1 corrector GLPG2222 on top of ivacaftor (Kalydeco ®[1] ) in heterozygous Class III/F508del CFTR patients Patient study recruited within 5 months in Europe and Australia GLPG2222 was well tolerated dosed [...]

Veritas Pharma Enters Binding Letter of Intent to Secure ACMPR License and Cannabis Growing Facility

18/11/2017 - 22:44

VANCOUVER, British Columbia, Nov. 18, 2017 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt: 2VP ), ( “Veritas” or the “Company” ), an emerging-stage pharmaceutical and IP development company, is [...]

Anthera Pharmaceuticals Announces Receipt of Nasdaq Listing Determination Notice and Plans Appeal

17/11/2017 - 22:05

Delisting notice was expected as part of the compliance extension previously granted by Nasdaq Continue “ANTH” listing until formal hearing process is complete with the Nasdaq Hearings Panel HAYWARD, Calif., Nov. 17, [...]

Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties

17/11/2017 - 18:55

Valby, Denmark, 2017-11-17 18:55 CET (GLOBE NEWSWIRE) -- Valby, Denmark, 17 November 2017 – H. Lundbeck A/S (Lundbeck) hereby publishes and reports transactions made by executives and persons closely associated with [...]

CrownBio Launches an Innovative Grant Program to Fund Advancements in Preclinical Oncology Research

17/11/2017 - 17:53

SANTA CLARA, Calif., Nov. 17, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company [...]